Konstantinova T S, Shalaev V A, Shpeer E L, Terskikh V A, Nizhechik Iu S
Ter Arkh. 1996;68(7):17-21.
Enzyme immunoassay has been used in 102 patients with acute leukemia (AL) and 340 donors to identify serological markers of hepatitis B virus (HBV) and hepatitis C virus (HCV): HB-sAg, anti-HBs, anti-HBc, anti-HBc IgM, HBeAg, anti-HBe. At the moment of AL diagnosis in 50 patients with acute myeloid leukemia and in 28 patients with acute lymphoblastic leukemia at least one HBV marker was found in 68% and 71%, respectively, HBsAg in 12% of patients with AML and 25% of those with ALL. In remission maintenance, HBsAg was registered in 83% of patients with AML and 44% of those with ALL. Anti-HCV in diagnosis of acute leukemia were detected in 1.28% of patients, 12 months after in 40% with ALL and 67% with AML. In examination of the donors at least one HBV marker was found in 36%, HBsAg in 2.1%, anti-HCV in 1.86% of the examinees. It is inferred that acute leukemia patients are often infected with HBV and in long-term follow-up demonstrate reactivation of viral infection, though infection with mutant B viruses is also possible. HCV is a main cause of posttransfusion hepatitis in this group of patients.
酶免疫测定法已用于102例急性白血病(AL)患者和340名供者,以鉴定乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)的血清学标志物:HBsAg、抗-HBs、抗-HBc、抗-HBc IgM、HBeAg、抗-HBe。在50例急性髓系白血病患者和28例急性淋巴细胞白血病患者诊断为急性白血病时,分别有68%和71%的患者至少发现一种HBV标志物,12%的急性髓系白血病患者和25%的急性淋巴细胞白血病患者检测到HBsAg。在缓解维持期,83%的急性髓系白血病患者和44%的急性淋巴细胞白血病患者检测到HBsAg。急性白血病诊断时,1.28%的患者检测到抗-HCV,12个月后,40%的急性淋巴细胞白血病患者和67%的急性髓系白血病患者检测到抗-HCV。在对供者的检查中,36%的受检者至少发现一种HBV标志物,2.1%的受检者检测到HBsAg,1.86%的受检者检测到抗-HCV。据推断,急性白血病患者常感染HBV,在长期随访中病毒感染会重新激活,不过也可能感染变异的B病毒。HCV是该组患者输血后肝炎的主要原因。